Publications by authors named "Rob Zuiker"

Claim this Profile
S
Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.
Katelijne V van der Heijden, Rob G J A Zuiker, Marije E Otto, Christopher S Bryan, Nancy Stewart

Clin Transl Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function.
Massimo Magliocca, Ingrid Koopmans, Cedric Vaillant, Vincent Lemoine, Rob Zuiker

J Psychopharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonazepam repurposing in patients through conventional RCT and N-of-1 trials: an experimental strategy for orphan disease development.
Pleuntje J van der Sluijs, Koshar Safai Pour, Cécile L Berends, Matthijs D Kruizinga, Annelieke R Müller, Rob G J A Zuiker

J Med Genet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant.
Ingrid Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Rob Zuiker

Clin Transl Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of oxathridine, a first-in-class histamine-3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo-hallucinations.
Francis M Dijkstra, Rob G J A Zuiker, Jules A A C Heuberger, Kawita M S Kanhai, Marieke De Kam

Br J Clin Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation.
Ingrid Koopmans, Robert-Jan Doll, Hein van der Wall, Marieke de Kam, Geert Jan Groeneveld, Rob Zuiker

PLoS One· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects.
Hemme Hijma, Ingrid Koopmans, Erica Klaassen, Robert Jan Doll, Rob Zuiker

Br J Clin Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.
Francis Dijkstra, Patricio O'Donnell, Erica Klaassen, Derek Buhl, Mahnaz Asgharnejad, Rob Zuiker

Transl Psychiatry· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers.
Francis M Dijkstra, Rob G J A Zuiker, Pieter S Siebenga, Richard A Leigh-Pemberton, Lei Sun

Br J Clin Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator.
Clemens Muehlan, Sander Brooks, Cedric Vaillant, Michael Meinel, Gabriël E Jacobs, Rob G Zuiker

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations.
Matthijs D Kruizinga, Rob G J A Zuiker, Kirsten R Bergmann, Annelies C Egas, Adam F Cohen

Br J Clin Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation.
Boudewijn van den Berg, Hemme J Hijma, Ingrid Koopmans, Robert J Doll, Rob G J A Zuiker

Exp Brain Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.
Robert Rissmann, Rob Zuiker

Br J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Study of Novel Exploratory Tools, Digital Technologies, and Central Nervous System Biomarkers to Characterize Unipolar Depression.
Oleksandr Sverdlov, Jelena Curcic, Kristin Hannesdottir, Liangke Gou, Valeria De Luca, Rob Zuiker

Front Psychiatry· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation.
Patricio O'Donnell, Francis M Dijkstra, Ugur Damar, Lei Quanhong, Annika A de Goede, Rob Zuiker

Transl Psychiatry· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects.
Clemens Muehlan, Rob Zuiker, Pierre Peeters, Racheal Rowles, Jasper Dingemanse

J Clin Psychopharmacol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
Benjamin Berger, Sander Brooks, Rob Zuiker, Muriel Richard, Clemens Muehlan

CNS Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
Kasper Recourt, Jasper van der Aart, Gabriel Jacobs, Marieke de Kam, Wayne Drevets, Rob Zuiker

J Psychopharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans.
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, Philip L Johnson, Brian Lord, Rob Zuiker

Transl Psychiatry· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding Suitable Clinical Endpoints for a Potential Treatment of a Rare Genetic Disease: the Case of ARID1B.
Matthijs D Kruizinga, Rob G J A Zuiker, Elif Sali, Marieke L de Kam, Robert J Doll

Neurotherapeutics· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Clemens Muehlan, Margaux Boehler, Sander Brooks, Rob Zuiker, Joop van Gerven

J Psychopharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis.
Matthijs D Kruizinga, Willem A J Birkhoff, Michiel J van Esdonk, Naomi B Klarenbeek, Tomasz Cholewinski, Rob G J A Zuiker

Br J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent

Transl Psychiatry· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
Clemens Muehlan, Sander Brooks, Rob Zuiker, Joop van Gerven, Jasper Dingemanse

Eur Neuropsychopharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis